Tips for erythropoiesis-stimulating agent treatment of renal anemia

被引：0
|
作者：
Naohisa Tomosugi
Yoshitaka Koshino
机构：
[1] Kanazawa Medical University,Medical Research Institute
[2] Mizuho Hospital,undefined
来源：
Clinical and Experimental Nephrology | 2020年 / 24卷
关键词：
Renal anemia; Erythropoiesis-stimulating agent; Red blood cell; Mean corpuscular hemoglobin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：105 / 106
页数：1
相关论文
共 50 条
  • [21] Hepcidin as a predictive factor and therapeutic target in erythropoiesis-stimulating agent treatment for anemia of chronic disease in rats
    Theurl, Milan
    Nairz, Manfred
    Schroll, Andrea
    Sonnweber, Thomas
    Asshoff, Malte
    Haschka, David
    Seifert, Markus
    Willenbacher, Wolfgang
    Wilflingseder, Doris
    Posch, Wilfried
    Murphy, Anthony T.
    Witcher, Derrick R.
    Theurl, Igor
    Weiss, Guenter
    [J]. HAEMATOLOGICA, 2014, 99 (09) : 1516 - 1524
  • [22] Erythropoiesis-stimulating agents for the treatment of myelodysplastic syndrome-related anemia
    Gascon, P.
    Krendyukov, A.
    Mathieson, N.
    Aapro, M.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 201 - 201
  • [23] ERYTHROPOIESIS-STIMULATING AGENT FOR TREATMENT OF ANEMIA AMELIORATES DETERIORATION OF ERYTHROCYTE DEFORMABILITY ASSOCIATED WITH CHRONIC KIDNEY DISEASE
    Aizawa, Ken
    Kawasaki, Ryohei
    Tashiro, Yoshihito
    Shimonaka, Yasushi
    Hirata, Michinori
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32
  • [24] Eisen- und ESA*-Therapie bei renaler AnämieIron and erythropoiesis-stimulating agent therapy for renal anemia
    R.M. Schaefer
    L. Schaefer
    [J]. Der Nephrologe, 2008, 3 (2): : 88 - 95
  • [25] Erythropoiesis-stimulating agents—benefits and harms in the treatment of anemia in cancer patients
    Ronald Heregger
    Richard Greil
    [J]. memo - Magazine of European Medical Oncology, 2023, 16 : 259 - 262
  • [26] Treatment of anemia of the cancer patient by an erythropoiesis stimulating agent
    Levy-Chavagnat, Diane
    [J]. ACTUALITES PHARMACEUTIQUES, 2011, 50 (506): : 17 - 18
  • [27] Factors associated with erythropoiesis-stimulating agent hyporesponsiveness anemia in chronic kidney disease patients
    Amnuay, Kamalas
    Srisawat, Nattachai
    Wudhikarn, Kitsada
    Assanasen, Thamathorn
    Polprasert, Chantana
    [J]. HEMATOLOGY REPORTS, 2019, 11 (03) : 61 - 64
  • [28] Impact of changing erythropoiesis-stimulating agent on the management of renal anaemia in haemodialysis patients
    Frank, C. L.
    [J]. PHARMACY WORLD & SCIENCE, 2008, 30 (04): : 478 - 479
  • [29] Erythropoiesis-Stimulating Agent Hyporesponsiveness in End-Stage Renal Disease Patients
    Ogawa, Tetsuya
    Nitta, Kosaku
    [J]. CHRONIC KIDNEY DISEASES - RECENT ADVANCES IN CLINICAL AND BASIC RESEARCH, 2015, 185 : 76 - 86
  • [30] History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology
    Kalantar-Zadeh, Kamyar
    [J]. AMERICAN JOURNAL OF NEPHROLOGY, 2017, 45 (03) : 235 - 247
12345